Physician profile
Daniel Haithcock
NPI 1275635427
$33,113.49
in general payments reported to CMS, 2019-2025
37 companies · $1,297 in 2025
The $1,297 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,375 · 2020: $8,174 · 2021: $8,828 · 2022: $5,776 · 2023: $2,607 · 2024: $4,056 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,289 · Food and Beverage: $3,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,289.03 |
| Food and Beverage | $3,671.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,531.59 | 2019-2023 | Jardiance |
| Abbott Laboratories | $5,626.24 | 2019-2025 | Aveir, Ensite, Ensite Precision |
| Lilly USA, LLC | $5,222.50 | 2020-2022 | |
| Boston Scientific Corporation | $3,024.06 | 2019-2025 | Watchman Flx, Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Medtronic, INC. | $1,501.92 | 2021-2025 | Evera Mri Xt Dr Surescan, Selectsecure, Aurora Ev-Icd Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $575.17 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $377.32 | 2019-2025 | |
| Cardiva Medical, INC. | $368.84 | 2021-2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| E.R. Squibb & Sons, L.L.C. | $347.40 | 2019-2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $312.17 | 2019-2020 | |
| Pfizer INC. | $271.77 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $248.16 | 2019-2024 | Xarelto |
| Atricure, INC. | $241.73 | 2019-2023 | |
| Biosense Webster, INC. | $239.18 | 2019-2021 | |
| Biotronik INC. | $133.84 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $129.61 | 2020-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Amgen INC. | $123.64 | 2019-2022 | |
| Smith+Nephew, INC. | $85.66 | 2019 | |
| Cvrx, INC. | $81.03 | 2022-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals Lp | $77.00 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $68.02 | 2021-2024 | Verquvo |
| Bridgebio Pharma, INC. | $60.88 | 2025 | Attruby |
| Novo Nordisk INC | $57.86 | 2021-2024 | Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $47.95 | 2019-2024 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $46.93 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $43.30 | 2019-2025 | Opsumit |
| Scpharmaceuticals INC. | $41.87 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.08 | 2025 | |
| Edwards Lifesciences Corporation | $35.84 | 2024 | Sapien 3 Ultra Resilia |
| Irhythm Technologies, INC. | $29.28 | 2024 | Zio Monitor, Zio Xt Patch |
| Portola Pharmaceuticals, LLC | $24.10 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $22.12 | 2025 | Rhythm Express |
| Regeneron Healthcare Solutions, INC. | $17.58 | 2019 | |
| Glaxosmithkline, LLC. | $17.26 | 2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $15.52 | 2024 | Nexletol |
| Acutus Medical, INC. | $15.41 | 2020 | |
| Elutia, INC. | $14.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Haithcock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.